))
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
Manage episode 390913957 series 2838329
内容由VJHemOnc提供。所有播客内容（包括剧集、图形和播客描述）均由 VJHemOnc 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made.
At the 65th ASH Annual Meeting and Exposition, leading experts Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shared their key highlights in MPNs, commenting on ongoing trials and promising combinations being explored, as well as future outlooks.
200集单集
分享
